Design Therapeutics, Inc. — Director's Dealing 2021

Oct 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-10-01

Reporting Person: Burgess Julie (Chief Accounting Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-01	Stock Option (right to buy)	$14.99	A	135000	Acquired	2031-09-30	Common Stock (135000)	Direct

Footnotes

F1: 25% of the shares vest one year after September 13, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.